Trametinib is a pyridopyrimidine that is currently employed as treatment for metastatic melanoma through direct inhibition of mitogen-activated protein kinase kinase 1 and 2 (MEK1/2), an upstream signaling protein of ERK activation (Khan et al., 2020). Here, MAP2K1 is linked to metastatic melanoma.